{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:45Z","timestamp":1707525165714},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"DOI":"10.7759\/cureus.40354","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T11:08:02Z","timestamp":1686654482000},"source":"Crossref","is-referenced-by-count":0,"title":["Antisynthetase Syndrome With Paraneoplastic Antibodies"],"prefix":"10.7759","author":[{"given":"Ashbina","family":"Pokharel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Karageorgiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tucker","family":"Billups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01388-0","article-title":"Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities-a case report with literature review","volume":"21","author":"Alfraji N","year":"2021","unstructured":"Alfraji N, Mazahir U, Chaudhri M, Miskoff J. Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities-a case report with literature review. BMC Pulm Med. 2021, 21:11. 10.1186\/s12890-020-01388-0","journal-title":"BMC Pulm Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors GR","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest. 2010, 138:1464-74. 10.1378\/chest.10-0180","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon J","year":"2011","unstructured":"Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011, 37:100-9. 10.1590\/s1806-37132011000100015","journal-title":"J Bras Pneumol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.024","article-title":"Hematological malignancy associated with polymyositis and dermatomyositis","volume":"11","author":"Marie I","year":"2012","unstructured":"Marie I, Guillevin L, Menard JF, et al.. Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev. 2012, 11:615-20. 10.1016\/j.autrev.2011.10.024","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez I","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al.. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford). 2017, 56:999-1007. 10.1093\/rheumatology\/kex021","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi J","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, Wang G. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017, 44:1051-7. 10.3899\/jrheum.161480","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3923-19","article-title":"Anti-ej antibody-positive anti-synthetase syndrome associated with retroperitoneal sarcoma","volume":"59","author":"Fukui S","year":"2020","unstructured":"Fukui S, Kobayashi K, Fujita Y, et al.. Anti-ej antibody-positive anti-synthetase syndrome associated with retroperitoneal sarcoma. Intern Med. 2020, 59:2071-6. 10.2169\/internalmedicine.3923-19","journal-title":"Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13920","article-title":"EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib","volume":"12","author":"Hara R","year":"2021","unstructured":"Hara R, Kanazu M, Iwai A, et al.. EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. Thorac Cancer. 2021, 12:1441-4. 10.1111\/1759-7714.13920","journal-title":"Thorac Cancer"},{"key":"ref9","article-title":"Antibody to Jo-1 in polymyositis\/dermatomyositis: association with interstitial pulmonary disease","volume":"11","author":"Hochberg MC","year":"1984","unstructured":"Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis\/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984, 11:663-5.","journal-title":"J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872615","article-title":"Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease","volume":"13","author":"Zhao N","year":"2022","unstructured":"Zhao N, Jiang W, Wu H, et al.. Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front Immunol. 2022, 13:872615. 10.3389\/fimmu.2022.872615","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/8xj0b9","article-title":"Defining anti-synthetase syndrome: a systematic literature review","volume":"40","author":"Zanframundo G","year":"2022","unstructured":"Zanframundo G, Faghihi-Kashani S, Scir\u00e8 CA, et al.. Defining anti-synthetase syndrome: a systematic literature review. Clin Exp Rheumatol. 2022, 40:309-19. 10.55563\/clinexprheumatol\/8xj0b9","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.2174\/0929867322666150514094935","article-title":"Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management","volume":"22","author":"Mirrakhimov AE","year":"2015","unstructured":"Mirrakhimov AE. Antisynthetase syndrome: a review of etiopathogenesis, diagnosis and management. Curr Med Chem. 2015, 22:1963-75.","journal-title":"Curr Med Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.959653","article-title":"A multidisciplinary approach to the diagnosis of antisynthetase syndrome","volume":"9","author":"Wells M","year":"2022","unstructured":"Wells M, Alawi S, Thin KY, et al.. A multidisciplinary approach to the diagnosis of antisynthetase syndrome. Front Med (Lausanne). 2022, 9:959653. 10.3389\/fmed.2022.959653","journal-title":"Front Med (Lausanne)"},{"key":"ref14","article-title":"Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome","volume":"1","author":"Martins P","year":"2022","unstructured":"Martins P, Dourado E, Melo AT, et al.. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome. ARP Rheumatol. 2022, 1:190-6.","journal-title":"ARP Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto M","year":"2019","unstructured":"Gasparotto M, Gatto M, Saccon F, Ghirardello A, Iaccarino L, Doria A. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol. 2019, 31:603-10. 10.1097\/BOR.0000000000000663","journal-title":"Curr Opin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay L","year":"2018","unstructured":"Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol. 2018, 30:664-73. 10.1097\/BOR.0000000000000555","journal-title":"Curr Opin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: a distinct disease spectrum","volume":"5","author":"Huang K","year":"2020","unstructured":"Huang K, Aggarwal R. Antisynthetase syndrome: a distinct disease spectrum. J Scleroderma Relat Disord. 2020, 5:178-91. 10.1177\/2397198320902667","journal-title":"J Scleroderma Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome - much more than just a myopathy","volume":"51","author":"Opinc AH","year":"2021","unstructured":"Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum. 2021, 51:72-83. 10.1016\/j.semarthrit.2020.09.020","journal-title":"Semin Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna L","year":"2019","unstructured":"Cavagna L, Trallero-Aragu\u00e1s E, Meloni F, et al.. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019, 8:10.3390\/jcm8112013","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.44.12.2241","article-title":"Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity","volume":"44","author":"Dalmau J","year":"1994","unstructured":"Dalmau J, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology. 1994, 44:2241-6. 10.1212\/wnl.44.12.2241","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/163603-antisynthetase-syndrome-with-paraneoplastic-antibodies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:58Z","timestamp":1707508918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/163603-antisynthetase-syndrome-with-paraneoplastic-antibodies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.40354","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}